Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
NCT01998035 · Columbia University · PHASE1/PHASE2 · terminated · last registry update 2024-08-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “PI left institution” | – | Registry record, Columbia University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HDAC1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-06-12Results posted on the registry: National Cancer Institute (NCI), Romidepsin + Lenalidomide (NCT04447027)
- 2025-06-08Results posted on the registry: Columbia University, Panobinostat 15 MG (NCT04804709)
- 2025-06-08Also stopped (terminated): Columbia University, Panobinostat 15 MG (NCT04804709)
- 2025-05-26Also stopped (terminated): Mayo Clinic, Belinostat + Carfilzomib (NCT03432741)
- 2025-05-16Also stopped (terminated): Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Romidepsin + Abraxane (NCT01938833)
- 2025-05-04Results posted on the registry: H. Lee Moffitt Cancer Center and Research Institute, Vorinostat + Pembrolizumab (NCT02638090)
- 2025-05-02Also stopped (terminated): Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Panobinostat (NCT01324635)
- 2025-04-16Results posted on the registry: New Approaches to Neuroblastoma Therapy Consortium, Dinutuximab + Vorinostat (NCT03332667)
- 2025-04-15Also stopped (withdrawn): National Institute of Neurological Disorders and Stroke (NINDS), Vorinostat (NCT04339751)
- 2025-04-04Also stopped (withdrawn): Case Comprehensive Cancer Center, Cisplatin + Vorinostat (NCT05608369)
- 2025-03-20Results posted on the registry: Roberto Pili, Atezolizumab + Bevacizumab (NCT03024437)
- 2025-03-20Also stopped (terminated): Roberto Pili, Atezolizumab + Bevacizumab (NCT03024437)
- 2025-03-20Results posted on the registry: Syndax Pharmaceuticals, entinostat + pembrolizumab (NCT02437136)
- 2025-03-18Results posted on the registry: M.D. Anderson Cancer Center, Busulfan + Gemcitabine Hydrochloride (NCT02506959)
- 2025-03-07Results posted on the registry: Spanish Lung Cancer Group, Vorinostat plus Erlotinib (NCT00503971)
- 2025-03-07Also stopped (terminated): Spanish Lung Cancer Group, Vorinostat plus Erlotinib (NCT00503971)
- 2025-02-24Also stopped (terminated): Australian & New Zealand Children's Haematology/Oncology Group, Panobinostat (NCT04897880)
- 2025-02-10Also stopped (terminated): Biodexa Pharmaceuticals, MTX110 (NCT05324501)
- 2025-01-24Results posted on the registry: Italfarmaco, Givinostat (NCT05860114)
- 2025-01-06Results posted on the registry: Italfarmaco, Givinostat 10 mg/mL + Midazolam 1mg/ml IV (NCT05492318)
- 2024-11-18Results posted on the registry: Nabil Adra, Pembrolizumab + Vorinostat (NCT02619253)
- 2024-11-18Results posted on the registry: Italfarmaco, Givinostat + Placebo (NCT03238235)
- 2024-11-12Also stopped (terminated): National Cancer Institute (NCI), Carboplatin + Paclitaxel (NCT01413750)
- 2024-11-07Results posted on the registry: Memorial Sloan Kettering Cancer Center, Romidepsin + Lenalidomide (NCT01755975)
- 2024-10-15Also stopped (withdrawn): Virginia Commonwealth University, Vorinostat Oral Capsule Group 1 + Vorinostat Oral Capsule Group 2 (NCT03263533)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision